TLDR:
– This week on “The Readout LOUD,” STAT’s biotech podcast, the hosts discuss the challenges faced by biotech startups in securing funding from venture capitalists during the industry’s downturn.
– They also delve into Gilead Sciences’ struggle to enter the oncology field and the recent acquisition of biotech firm Inhibrx by a major pharmaceutical company.
In this episode of “The Readout LOUD,” the hosts tackle several key topics in the biotech industry:
1. The Challenges Faced by Biotech Startups:
– The downturn in the biotech industry has made it increasingly difficult for startups to secure funding from venture capitalists.
– The hosts discuss the impact of this funding shortage and how it is affecting the development and growth of these companies.
2. Gilead Sciences’ Struggle to Enter Oncology:
– Gilead Sciences, known for its expertise in antiviral drugs such as remdesivir, has been trying to establish itself in the field of oncology.
– The hosts explore the challenges and setbacks faced by Gilead in its pursuit of becoming an oncology company.
3. Acquisition of Inhibrx:
– Inhibrx, a biotech firm focused on the development of novel biologic therapies, was recently acquired by a major pharmaceutical company.
– The hosts analyze the implications of this acquisition and the potential impact on the biotech industry.
The hosts provide additional resources and links for listeners to further explore these topics, including more information on Gilead Sciences, news about Inhibrx, updates on biotech venture capital, episodes of the podcast Color Code, and subscriptions to the First Opinion Podcast and The Readout newsletter.
Overall, this episode of “The Readout LOUD” offers valuable insights into the challenges faced by biotech startups, the struggles of a major pharmaceutical company in entering a new field, and the dynamics of M&A activity in the biotech industry. Listeners can gain a deeper understanding of these issues and their potential implications for the industry as a whole.
